Psyence BioMed unit signs term sheet for exclusive US ibogaine license, supply deal with PsyLabs
Bitget2026/09/28 11:02- Psyence Biomedical’s Texas unit TIRC signed a binding term sheet for an exclusive U.S. license to PsyLabs’ pharmaceutical-grade ibogaine.
- Definitive agreement targeted by Nov. 30, 2026; term sheet lapses if no deal is signed by that date.
- Arrangement includes exclusive U.S. supply from PsyLabs, with TIRC as exclusive U.S. wholesaler and distributor.
- Economics include up to about USD 1.3 million in development and regulatory milestones for the first drug candidate.
- Also includes an annual exclusivity fee starting after first FDA approval, plus low single-digit royalties on net sales.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CNN Enters Generative AI Partnership with Google
US Stock Market Movement | Nvidia-backed AI pharmaceutical company Iambic Therapeutics (IAM.US) debuts on Nasdaq, surging over 11% after opening
As of press time, the stock is up more than 11%, trading at $17.77.
US Stock Market Movement | 3D Printing Materials Supplier Amaero (AMRO.US) Debuts on US Stock Market, Trading Halt Triggered After Opening
Amaero, a manufacturer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has gone public on the US stock market.
Crypto prices
More
